Author: admin

Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the Non Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non Cystic Fibrosis Bronchiectasis Treatment Landscape @ Non Cystic Fibrosis Bronchiectasis Pipeline Outlook

Key Takeaways from the Non Cystic Fibrosis Bronchiectasis Pipeline Report

  • On 17 August 2025, Verona Pharma plc announced a study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
  • DelveInsight’s Non Cystic Fibrosis Bronchiectasis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non Cystic Fibrosis Bronchiectasis treatment.
  • The leading Non Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Promising Non Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.

Stay informed about the cutting-edge advancements in Non Cystic Fibrosis Bronchiectasis treatments. Download for updates and be a part of the revolution in Respiratory Diseases Care @ Non Cystic Fibrosis Bronchiectasis Clinical Trials Assessment

Non Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

  • Brensocatib: Insmed Incorporated

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Insmed acquired the license for the treatment from AstraZeneca in 2016. Currently, the drug is in Phase III stage of its clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

  • HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.

  • CSL 787: CSL Behring

CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non‐cystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

The Non Cystic Fibrosis Bronchiectasis Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Cystic Fibrosis Bronchiectasis Treatment.
  • Non Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Cystic Fibrosis Bronchiectasis market.

Learn more about Non Cystic Fibrosis Bronchiectasis Drugs opportunities in our groundbreaking Non Cystic Fibrosis Bronchiectasis research and development projects @ Non Cystic Fibrosis Bronchiectasis Unmet Needs

Non Cystic Fibrosis Bronchiectasis Companies

Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.

Non‐cystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Non Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Stay informed about how we’re transforming the future of Respiratory Disease @ Non Cystic Fibrosis Bronchiectasis Market Drivers and Barriers, and Future Perspectives

Scope of the Non Cystic Fibrosis Bronchiectasis Pipeline Report

  • Coverage- Global
  • Non Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Non Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.
  • Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Non Cystic Fibrosis Bronchiectasis Pipeline on our website @ Non Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non‐cystic fibrosis bronchiectasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non‐cystic fibrosis bronchiectasis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Brensocatib: Insmed Incorporated
  9. Mid Stage Products (Phase II)
  10. HSK31858: Haisco Pharmaceutical Group Co., Ltd.
  11. Early Stage Products (Phase I)
  12. CSL 787: CSL Behring
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Non‐cystic fibrosis bronchiectasis Key Companies
  17. Non‐cystic fibrosis bronchiectasis Key Products
  18. Non‐cystic fibrosis bronchiectasis- Unmet Needs
  19. Non‐cystic fibrosis bronchiectasis- Market Drivers and Barriers
  20. Non‐cystic fibrosis bronchiectasis- Future Perspectives and Conclusion
  21. Non‐cystic fibrosis bronchiectasis Analyst Views
  22. Non‐cystic fibrosis bronchiectasis Key Companies
  23. 23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Parkinson’s disease psychosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment, Pipeline | Vanda Pharmaceuticals, Sumitomo Pharma

“Parkinson’s disease psychosis Clinical Trials”
DelveInsight’s, “Parkinson’s disease psychosis – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parkinson’s disease psychosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Parkinson’s disease psychosis pipeline includes over five key companies actively developing more than five investigational therapies.

Parkinson’s disease psychosis Overview:

Nonmotor symptoms have a major impact on the quality of life of Parkinson’s disease (PD) patients and their caregivers, and growing awareness among healthcare professionals highlights their significance. Psychosis is among the most common and debilitating nonmotor symptoms, affecting 20% to 70% of patients in advanced PD stages. It usually emerges in individuals with an intact sensorium during chronic disease progression and is often precipitated or exacerbated by medications. Recent research, however, points to additional risk factors, indicating a multifactorial origin and complex underlying mechanisms. The classification of early- versus late-onset psychosis, both generally and within PD, remains unstandardized, with some studies defining early-onset psychosis as occurring within 2–4 years of PD diagnosis.

Request for a detailed insights report on Parkinson’s disease psychosis pipeline insights

“Parkinson’s disease psychosis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson’s disease psychosis Therapeutics Market.

Key Takeaways from the Parkinson’s disease psychosis Pipeline Report

  • DelveInsight’s Parkinson’s disease psychosis pipeline report highlights an active landscape, with over five companies developing more than five investigational therapies for the treatment of Parkinson’s disease psychosis.

  • Leading companies in this space, including Vanda Pharmaceuticals, Sumitomo Pharma, and others, are advancing new drugs to enhance the treatment options for this condition. Promising pipeline candidates in various stages of development include Iloperidone, Ulotaront, and additional therapies.

  • AbbVie Inc. has been developing tavapadon, a selective D1/D5 receptor partial agonist, for early-stage Parkinson’s disease. In December 2025, AbbVie reported positive outcomes from a third Phase 3 trial, showing notable improvements in motor function, and plans to pursue FDA approval later in 2025.

Parkinson’s disease psychosis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Parkinson’s disease psychosis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s disease psychosis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson’s disease psychosis market.

Download our free sample page report on Parkinson’s disease psychosis pipeline insights

Parkinson’s disease psychosis Emerging Drugs

  • Iloperidone: Vanda Pharmaceuticals

  • Ulotaront: Sumitomo Pharma

Parkinson’s disease psychosis Companies

Over five leading companies are actively working on therapies for Parkinson’s disease psychosis, with Vanda Pharmaceuticals having a candidate in the most advanced stage, currently in Phase II clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Parkinson’s disease psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Parkinson’s disease psychosis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson’s disease psychosis Therapies and Key Companies: Parkinson’s disease psychosis Clinical Trials and advancements

Parkinson’s disease psychosis Pipeline Therapeutic Assessment

• Parkinson’s disease psychosis Assessment by Product Type

• Parkinson’s disease psychosis By Stage

• Parkinson’s disease psychosis Assessment by Route of Administration

• Parkinson’s disease psychosis Assessment by Molecule Type

Download Parkinson’s disease psychosis Sample report to know in detail about the Parkinson’s disease psychosis treatment market @ Parkinson’s disease psychosis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Parkinson’s disease psychosis Current Treatment Patterns

4. Parkinson’s disease psychosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Parkinson’s disease psychosis Late-Stage Products (Phase-III)

7. Parkinson’s disease psychosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Parkinson’s disease psychosis Discontinued Products

13. Parkinson’s disease psychosis Product Profiles

14. Parkinson’s disease psychosis Key Companies

15. Parkinson’s disease psychosis Key Products

16. Dormant and Discontinued Products

17. Parkinson’s disease psychosis Unmet Needs

18. Parkinson’s disease psychosis Future Perspectives

19. Parkinson’s disease psychosis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Parkinson’s disease psychosis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s disease psychosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment, Pipeline | Vanda Pharmaceuticals, Sumitomo Pharma

Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Migraine Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Migraine Treatment Landscape. Click here to read more @ Migraine Pipeline Outlook

Key Takeaways from the Migraine Pipeline Report

  • On 17 August 2025, Teva Branded Pharmaceutical Products R&D LLC announced a study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study).
  • On 15 August 2025, Pfizer conducted a study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue.
  • On 15 August 2025, AbbVie announced a study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. The study will include 2 cohorts of participants – PK Cohort and Main Study (non-PK cohort)
  • DelveInsight’s Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment.
  • The leading Migraine Companies such as ​Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.
  • Promising Migraine Pipeline Therapies such as ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others.

Stay informed about the cutting-edge advancements in Migraine Treatments. Download for updates and be a part of the revolution in Neurology care @ Migraine Clinical Trials Assessment

Migraine Emerging Drugs Profile

  • AXS-07: Axsome Therapeutics

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.

  • STS-101: Satsuma Pharmaceuticals

STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration.

  • Zavegepant: Biohaven Pharmaceuticals

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

  • TNX1900: Tonix Pharmaceuticals

TNX-1900(Oxytocin), Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication.

The Migraine pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
  • Migraine Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

Get a detailed analysis of the latest innovations in the Migraine pipeline. Explore DelveInsight’s expert-driven report today! @ Migraine Unmet Needs

Migraine Companies

Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Migraine Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Migraine Treatment by visiting our website. Stay informed about how we’re transforming the future of neurology @ Migraine Market Drivers and Barriers, and Future Perspectives

Scope of the Migraine Pipeline Report

  • Coverage- Global
  • Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.
  • Migraine Pipeline Therapies- ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others.
  • Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Migraine Pipeline on our website @ Migraine Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Migraine: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Migraine– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. AXS-07: Axsome Therapeutics
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. STS-101: Satsuma Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. TNX1900: Tonix Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Migraine Key Companies
  21. Migraine Key Products
  22. Migraine – Unmet Needs
  23. Migraine – Market Drivers and Barriers
  24. Migraine – Future Perspectives and Conclusion
  25. Migraine Analyst Views
  26. Migraine Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/migraine-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Asperger Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside

“Asperger Syndrome Market”
The leading Asperger Syndrome Companies working in the market include Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., and others.

 

Emerging therapies for Asperger Syndrome are anticipated to drive growth in the Asperger Syndrome market in the coming years.

 

DelveInsight has launched a new report on “Asperger Syndrome – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Asperger Syndrome, historical and forecasted epidemiology as well as the Asperger Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Request for our detailed sample pages on Asperger Syndrome Market report

 

 

Some of the key facts of the Asperger Syndrome Market Report:

 

  • The Asperger Syndrome market is anticipated to grow as awareness of the condition rises and more effective treatments and interventions are introduced.

  • Key companies operating in this market include Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., among others.

  • In June 2023, the State University of New York – Upstate Medical University announced a clinical trial study focused on salivary collection and the Mullen Scales of Early Learning. The research aims to validate a set of miRNAs capable of distinguishing children with autism spectrum disorder (ASD) from those who have a positive MCHAT-R result but do not have ASD. These biomarkers could enable earlier autism detection, leading to timely interventions, while also enhancing our understanding of neurological changes associated with autism in children.

 

Key benefits of the Asperger Syndrome market report:

  1. Asperger Syndrome market report covers a descriptive overview and comprehensive insight of the Asperger Syndrome Epidemiology and Asperger Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Asperger Syndrome market report provides insights on the current and emerging therapies.

  3. Asperger Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Asperger Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Asperger Syndrome market.

 

Got queries? Click here to know more about the Asperger Syndrome Market Landscape

 

 

Asperger Syndrome Overview

 

Asperger Syndrome, a developmental disorder on the autism spectrum, is generally managed using a personalized, multidisciplinary approach. Treatment aims to enhance social communication, address sensory sensitivities, and manage co-occurring conditions. Behavioral interventions, including Applied Behavior Analysis (ABA) and social skills training, play a key role in helping individuals improve social interactions and build relationships. Available therapies encompass both traditional and modern medical approaches, with established treatment guidelines and protocols followed in regions such as the United States, Europe, and Japan.

 

Asperger Syndrome Market Outlook

 

The Asperger Syndrome market is expected to undergo significant changes in the coming years, driven by the anticipated introduction of emerging therapies from leading companies such as Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., and others during the 2020–2034 forecast period.

 

Discover how the asperger syndrome market is rising in the upcoming years

 

 

Asperger Syndrome Key Companies: Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc.

 

Scope of the Asperger Syndrome Market Report

 

  • Study Period: 2020-2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Asperger Syndrome Companies: Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside Therapeutics Inc., Quadrant Biosciences Inc., and others

  • Asperger Syndrome Therapeutic Assessment: Asperger Syndrome current marketed and Asperger Syndrome emerging therapies

  • Asperger Syndrome Market Dynamics: Asperger Syndrome market drivers and Asperger Syndrome market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Asperger Syndrome Unmet Needs, KOL’s views, Analyst’s views, Asperger Syndrome Market Access and Reimbursement

 

Download sample pages @ https://www.delveinsight.com/sample-request/asperger-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

 

 

Table of Contents

 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Asperger Syndrome Patient Share (%) Overview at a Glance

5. Asperger Syndrome Market Overview at a Glance

6. Asperger Syndrome Disease Background and Overview

7. Asperger Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Asperger Syndrome

9. Asperger Syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. Asperger Syndrome Emerging Therapies

12. Asperger Syndrome Market Outlook

13. Country-Wise Asperger Syndrome Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Asperger Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Click here to read more about Asperger Syndrome Market Outlook 2034

 

Related Reports:

Asperger Syndrome Pipeline Insights, DelveInsight

“Asperger Syndrome Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Asperger Syndrome market. A detailed picture of the Asperger Syndrome pipeline landscape is provided, which includes the disease overview and Asperger Syndrome treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asperger Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | Hoffmann-La Roche, SymTrend Inc., Forest Laboratories, Bristol-Myers Squibb, CogCubed Corp, Obslap Research LLC, Seaside

Recurrent Glioblastoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the Recurrent Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Recurrent Glioblastoma Research. Learn more about our innovative pipeline today! @ Recurrent Glioblastoma Pipeline Outlook

Key Takeaways from the Recurrent Glioblastoma Pipeline Report

  • On 20 August 2025, CarThera conducted a study of brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated.
  • On 17 August 2025, Darell Bigner announced a study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
  • On 15 August 2025, University of Pennsylvania organized a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses.
  • DelveInsight’s Recurrent Glioblastoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Recurrent Glioblastoma treatment.
  • The leading Recurrent Glioblastoma Companies such as Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
  • Promising Recurrent Glioblastoma Pipeline Therapies such as Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.

Stay informed about the cutting-edge advancements in Recurrent Glioblastoma treatments. Download for updates and be a part of the revolution in care @ Recurrent Glioblastoma Clinical Trials Assessment

Recurrent Glioblastoma Emerging Drugs Profile

  • ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%.

  • GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy.

  • Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.

  • VXM01: VAXIMM AG

VXM01 is an oral T-cell immunotherapy that is designed to activate T-cells to attack the tumor vasculature and, in several tumor types, attack cancer cells directly. VXM01 carries the vascular endothelial growth factor receptor-2 (VEGFR2), which is highly overexpressed on the tumor vasculature and on certain cancer cells as the target gene. The active, T-cell-mediated destruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue (inflammation). In preclinical studies, a murine analog VXM01 vaccine showed broad anti-tumor activity in different tumor types. This activity was linked to a VEGFR2-specific T-cell response and was accompanied by the destruction of the tumor vasculature and increased immune cell infiltration. A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma is ongoing. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

The Recurrent Glioblastoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent Glioblastoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent Glioblastoma Treatment.
  • Recurrent Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Recurrent Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent Glioblastoma Market

Stay informed about the Recurrent Glioblastoma Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Recurrent Glioblastoma Unmet Needs

Recurrent Glioblastoma Companies

Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.

Recurrent Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Recurrent Glioblastoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Transform your understanding of the Recurrent Glioblastoma Pipeline! See the latest progress in drug development and clinical research @ Recurrent Glioblastoma Market Drivers and Barriers, and Future Perspectives

Scope of the Recurrent Glioblastoma Pipeline Report

  • Coverage- Global
  • Recurrent Glioblastoma Companies- Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., and Chimerix and others.
  • Recurrent Glioblastoma Pipeline Therapies- Pembrolizumab, Olaparib, Temozolomide, BIBF1120, Chemotherapy, GX-I7, Bevacizumab, Bevacizumab, TTAC-0001, Cediranib and others.
  • Recurrent Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Recurrent Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Recurrent Glioblastoma Pipeline Analysis Today! @ Recurrent Glioblastoma Drugs and Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Recurrent Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ASC40: Ascletis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GX-I7: Genexine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VXM01: VAXIMM AG
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Recurrent Glioblastoma Key Companies
  21. Recurrent Glioblastoma Key Products
  22. Recurrent Glioblastoma- Unmet Needs
  23. Recurrent Glioblastoma- Market Drivers and Barriers
  24. Recurrent Glioblastoma- Future Perspectives and Conclusion
  25. Recurrent Glioblastoma Analyst Views
  26. Recurrent Glioblastoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/recurrent-glioblastoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Glioblastoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Motor Neuron Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd

“Motor Neuron Disease Clinical Trials”
DelveInsight’s, “Motor Neuron Disease- Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that the Motor Neuron Disease pipeline involves over 180 key companies actively developing more than 200 investigational therapies.

Motor Neuron Disease Overview:

Motor neuron diseases (MNDs) are a group of progressive neurological disorders that damage motor neurons, the cells responsible for controlling vital muscle functions such as movement, breathing, speech, and swallowing. This group includes conditions like amyotrophic lateral sclerosis (ALS), primary lateral sclerosis, spinal muscular atrophy, and others. Although rare, MND is a serious condition that gradually weakens muscles, profoundly affecting daily activities. While no cure currently exists, treatments can help manage symptoms, and some patients live with the disease for many years. The causes of MND are multifactorial, involving genetic, environmental, and lifestyle factors, with approximately 10% of cases inherited due to genetic mutations.

Symptoms often develop slowly and may be subtle at first. Early indicators include weakness in the legs or ankles, difficulty speaking or swallowing, reduced grip strength, muscle cramps, weight loss, and involuntary emotional reactions such as sudden laughter or crying. The disease typically progresses through three stages—early, middle, and advanced—affecting individuals differently in terms of speed and severity. Ultimately, MND leads to a decline in physical function and reduces life expectancy.

Request for a detailed insights report on Motor Neuron Disease pipeline insights

“Motor Neuron Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Motor Neuron Disease Therapeutics Market.

Key Takeaways from the Motor Neuron Disease Pipeline Report

  • DelveInsight’s Motor Neuron Disease (MND) pipeline report highlights a vibrant landscape, with over 180 companies actively developing more than 200 investigational therapies for MND.

  • Key players in this field include Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd., Transposon Therapeutics, Inc., GeneCradle Therapeutics, Verge Genomics, QurAlis Corporation, Zydus Lifesciences Limited, Ra Pharmaceuticals, Guangzhou Magpie Pharmaceuticals Co., Ltd., Scholar Rock, Inc., Spinogenix, Seelos Therapeutics, Inc., Sanofi, Hoffmann-La Roche, Revalesio Corporation, Cytokinetics, Rapa Therapeutics LLC, Q Therapeutics, Inc., PTC Therapeutics, ProJenX, NeuroSense Therapeutics Ltd., Knopp Biosciences, MediciNova, Amylyx Pharmaceuticals Inc., Neuropore Therapies Inc., NMD Pharma A/S, Supernus Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma America Inc., MaaT Pharma, and others, all working to advance treatments and improve the therapeutic landscape for MND.

  • Promising pipeline candidates in various stages of development include Talditercept alfa, Pridopidine, VM202, TPN-101, GC 101, VRG 50635, QRL 201, and more.

  • In December 2024, Celosia Therapeutics, a biotech spin-out from Macquarie University, secured $16.8 million in funding to advance its ALS treatment, CTX-1000, into clinical trials. CTX-1000 is a disease-modifying therapy targeting the harmful protein TDP-43, which affects motor neurons in ALS patients. The therapy aims to halt disease progression with a single administration, showing promise even in severe animal models. Human trials are expected to commence by late 2025 at Macquarie University Hospital.

  • In October 2024, Scholar Rock announced positive results from a Phase 3 trial of Apitegromab, a treatment for spinal muscular atrophy (SMA). The therapy demonstrated significant improvements in motor function, with 30.4% of patients showing over a 3-point improvement on the Hammersmith Functional Motor Scale Expanded (HFMSE), compared to 12.5% on placebo. Scholar Rock plans to submit applications for U.S. Biologics License and European Union marketing authorization in early 2025.

  • In May 2024, the FDA cleared Spinogenix’s Investigational New Drug (IND) application for SPG302, a novel therapy aimed at treating Amyotrophic Lateral Sclerosis (ALS). SPG302 is designed as a once-daily oral treatment with the potential to regenerate synapses, thereby addressing declines in cognitive and motor functions associated with ALS.

Motor Neuron Disease Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Motor Neuron Disease Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Motor Neuron Disease treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Motor Neuron Disease market.

Download our free sample page report on Motor Neuron Disease pipeline insights

Motor Neuron Disease Emerging Drugs

  • Talditercept alfa: Biohaven Pharmaceuticals, Inc.

  • Pridopidine: Prilenia Therapeutics

  • VM202: Helixmith Co., Ltd.

  • TPN-101: Transposon Therapeutics, Inc.

  • GC 101: GeneCradle Therapeutics

  • VRG 50635: Verge Genomics

  • QRL 201: QurAlis Corporation

Motor Neuron Disease Companies

Over 180 leading companies are actively pursuing therapies for Motor Neuron Disease, with Biohaven Pharmaceuticals, Inc. having a candidate in the most advanced stage, currently undergoing Phase III clinical trials.

DelveInsight’s report covers around 200+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Motor Neuron Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Motor Neuron Disease Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Motor Neuron Disease Therapies and Key Companies: Motor Neuron Disease Clinical Trials and advancements

Motor Neuron Disease Pipeline Therapeutic Assessment

• Motor Neuron Disease Assessment by Product Type

• Motor Neuron Disease By Stage

• Motor Neuron Disease Assessment by Route of Administration

• Motor Neuron Disease Assessment by Molecule Type

Download Motor Neuron Disease Sample report to know in detail about the Motor Neuron Disease treatment market @ Motor Neuron Disease Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Motor Neuron Disease Current Treatment Patterns

4. Motor Neuron Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Motor Neuron Disease Late-Stage Products (Phase-III)

7. Motor Neuron Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Motor Neuron Disease Discontinued Products

13. Motor Neuron Disease Product Profiles

14. Motor Neuron Disease Key Companies

15. Motor Neuron Disease Key Products

16. Dormant and Discontinued Products

17. Motor Neuron Disease Unmet Needs

18. Motor Neuron Disease Future Perspectives

19. Motor Neuron Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Motor Neuron Disease Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Motor Neuron Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Biohaven Pharmaceuticals, Inc., Prilenia Therapeutics, Helixmith Co., Ltd

Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline

“Metastatic Non-small Cell Lung Cancer Clinical Trials”
DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that the Metastatic Non-Small Cell Lung Cancer pipeline includes over 25 key companies actively developing more than 30 treatment therapies.

Metastatic Non-small Cell Lung Cancer Overview:

Lung cancer remains a leading cause of cancer-related mortality worldwide, with generally poor outcomes. However, the advent of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has revolutionized treatment for non-small cell lung cancer (NSCLC). Blocking the PD-1/PD-L1 pathway has shown notable therapeutic benefits and improved survival in both preclinical and clinical settings for patients with locally advanced or metastatic NSCLC.

PD-1, a type I transmembrane protein, is expressed on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells. Its ligands, PD-L1 and PD-L2, are also type I transmembrane proteins but exhibit distinct expression patterns. PD-L1 is present on immune cells such as T cells, B cells, dendritic cells, and macrophages, as well as on various nonhematopoietic and tumor cells. Structurally, PD-1 and its ligands include a signal sequence, an immunoglobulin (Ig) domain, transmembrane regions, and a short cytoplasmic tail.

When PD-1 binds to PD-L1 or PD-L2, phosphorylation occurs at two tyrosine residues in its cytoplasmic domain. This triggers recruitment of the phosphatases SHP-1 and SHP-2, which interact with ITIM and ITSM motifs of PD-1, ultimately dampening antigen receptor signaling. This PD-1/ligand interaction suppresses effector T-cell activity, whereas the binding of B7-1/B7-2 to CD28 promotes T-cell proliferation.

Request for a detailed insights report on Metastatic Non-small Cell Lung Cancer pipeline insights

“Metastatic Non-small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Non-small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Metastatic Non-small Cell Lung Cancer Pipeline Report

  • DelveInsight’s report highlights a dynamic Metastatic Non-Small Cell Lung Cancer (NSCLC) pipeline, with over 25 companies actively developing more than 30 investigational therapies. Leading players in this space include Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, among others, all working to advance novel treatment options for metastatic NSCLC.

  • Several promising candidates—such as Zimberelimab, PM8002, RPH075, and others—are progressing through different stages of clinical development.

  • Recent regulatory approvals have further strengthened the treatment landscape. In August 2024, the FDA approved AstraZeneca’s durvalumab for adult NSCLC patients following surgery, broadening its indication beyond advanced cases unsuitable for surgery. Earlier, in January 2023, the FDA approved pembrolizumab as an adjuvant therapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC after surgical resection and platinum-based chemotherapy.

Metastatic Non-small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Metastatic Non-small Cell Lung Cancer Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Non-small Cell Lung Cancer treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Non-small Cell Lung Cancer market.

Download our free sample page report on Metastatic Non-small Cell Lung Cancer pipeline insights

Metastatic Non-small Cell Lung Cancer Emerging Drugs

  • Zimberelimab: Arcus Biosciences

  • PM8002: Biotheus

  • RPH075: R-Pharm

Metastatic Non-small Cell Lung Cancer Companies

Over 25 leading companies are actively working on therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC). Notably, Arcus Biosciences has drug candidates in the most advanced stage of development, currently in Phase III trials.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Metastatic Non-small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Metastatic Non-small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Non-small Cell Lung Cancer Therapies and Key Companies: Metastatic Non-small Cell Lung Cancer Clinical Trials and advancements

Metastatic Non-small Cell Lung Cancer Pipeline Therapeutic Assessment

• Metastatic Non-small Cell Lung Cancer Assessment by Product Type

• Metastatic Non-small Cell Lung Cancer By Stage

• Metastatic Non-small Cell Lung Cancer Assessment by Route of Administration

• Metastatic Non-small Cell Lung Cancer Assessment by Molecule Type

Download Metastatic Non-small Cell Lung Cancer Sample report to know in detail about the Metastatic Non-small Cell Lung Cancer treatment market @ Metastatic Non-small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Metastatic Non-small Cell Lung Cancer Current Treatment Patterns

4. Metastatic Non-small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Non-small Cell Lung Cancer Late-Stage Products (Phase-III)

7. Metastatic Non-small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Non-small Cell Lung Cancer Discontinued Products

13. Metastatic Non-small Cell Lung Cancer Product Profiles

14. Metastatic Non-small Cell Lung Cancer Key Companies

15. Metastatic Non-small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Metastatic Non-small Cell Lung Cancer Unmet Needs

18. Metastatic Non-small Cell Lung Cancer Future Perspectives

19. Metastatic Non-small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Non-small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Non-small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline

SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the SYK Inhibitor Treatment Landscape @ SYK Inhibitor Pipeline Outlook

Key Takeaways from the SYK Inhibitor Pipeline Report

  • DelveInsight’s SYK Inhibitor pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for SYK Inhibitor treatment.
  • The leading SYK Inhibitor Companies such as Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
  • Promising SYK Inhibitor Pipeline Therapies such as SKI-O-703, Entospletinib and others.

Stay informed about the cutting-edge advancements in SYK Inhibitor treatments. Download for updates and be a part of the revolution @ SYK Inhibitor Clinical Trials Assessment

SYK Inhibitor Emerging Drugs Profile

  • Cevidoplenib dimesylate: Genosco

The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.

  • HMPL-523: Hutchison MediPharma

An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.

The SYK Inhibitor Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of SYK Inhibitor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for SYK Inhibitor Treatment.
  • SYK Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • SYK Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the SYK Inhibitor market.

Learn more about SYK Inhibitor Drugs opportunities in our groundbreaking SYK Inhibitor research and development projects @ SYK Inhibitor Unmet Needs

SYK Inhibitor Companies

Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.

Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Molecule Type

SYK Inhibitor Products have been categorized under various Molecule types such as

  • Monoclonal antibodies
  • Small molecules
  • Product Type

Stay informed about how we’re transforming the future of SYK landscape @ SYK Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the SYK Inhibitor Pipeline Report

  • Coverage- Global
  • SYK Inhibitor Companies- Genosco, Portola Pharmaceuticals, GlaxoSmithKline, FUJIFILM Corporation, TopiVert, Takeda Oncology, Asana BioSciences and others.
  • SYK Inhibitor Pipeline Therapies- SKI-O-703, Entospletinib and others.
  • SYK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • SYK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of SYK Inhibitor Pipeline on our website @ SYK Inhibitor Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
  9. Late Stage Products (Phase II/III)
  10. TOP 1630: TopiVert
  11. Mid Stage Products (Phase II)
  12. Cevidoplenib: Genosco
  13. PRT 2761: Portola Pharmaceuticals
  14. Early Stage Products (Phase I/II)
  15. Gusacitinib: Asana BioSciences
  16. Early Stage Products (Phase I)
  17. Mivavotinib: Takeda Oncology
  18. Pre-clinical and Discovery Stage Products
  19. Research programme: small molecule therapeutics: Genosco
  20. Inactive Products
  21. Comparative Analysis
  22. Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spleen-tyrosine-kinase-syk-inhibitors-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SYK Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Mild Cognitive Impairment Market: Epidemiology, Therapies, Companies Working, DelveInsight | Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio, Inc., Anavex Life Sciences Corp., TauRx

“Mild Cognitive Impairment Market”
The Mild Cognitive Impairment market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Mild Cognitive Impairment market size from 2020 to 2034.

Emerging therapies for Mild Cognitive Impairment, including LEQEMBI (lecanemab), KISUNLA (donanemab), and others, are anticipated to drive growth in the Mild Cognitive Impairment market in the coming years.

 

DelveInsight has launched a new report on “Mild Cognitive Impairment – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Mild Cognitive Impairment, historical and forecasted epidemiology as well as the Mild Cognitive Impairment market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Download sample pages to know more about mild cognitive impairment market

 

 

Some of the key facts of the Mild Cognitive Impairment Market Report:

 

  • In 2023, the Mild Cognitive Impairment (MCI) market across the seven major markets (7MM) was valued at about USD 2.83 billion, with steady growth anticipated through 2034. The United States accounted for the largest share, generating nearly USD 1.47 billion in 2023, a figure expected to rise further over the forecast period.

  • DelveInsight estimates that in 2023, the U.S. had approximately 1.21 million diagnosed cases of Parkinson’s disease. Within Europe, Germany reported the highest number of Alzheimer’s cases at around 1.49 million, followed by France with 1.17 million, while the UK had the lowest prevalence at 620,000. Germany also led the EU4 and the UK in diagnosed MCI cases associated with Parkinson’s disease, recording nearly 223,000 cases in 2023, with numbers projected to increase by 2034. In the same year, the U.S. had the highest prevalence of Alzheimer’s among the 7MM, with an estimated 6.98 million cases, and this burden is expected to continue rising.

  • By share, the U.S. represented 42% of the MCI population across the 7MM, followed by Japan (27%), Germany (10%), and France (7%). Experts anticipate overall diagnosed cases to grow in the coming years. The current MCI treatment landscape includes approved drugs such as LEQEMBI (lecanemab) alongside off-label use of cholinesterase inhibitors and memantine, contributing to a market value of about USD 222 million in 2023. Market expansion is expected as new therapies emerge between 2024 and 2034.

  • A key milestone came in July 2024, when the U.S. FDA approved KISUNLA (donanemab-azbt, 350 mg/20 mL), developed by Eli Lilly, for the treatment of early symptomatic Alzheimer’s disease, including MCI and mild dementia with confirmed amyloid pathology.

  • Japan’s MCI market was valued at nearly USD 670 million in 2023, accounting for 24% of the 7MM market, and is also forecasted to grow by 2034.

  • Several major players—including Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio Inc., Anavex Life Sciences Corp., TauRx Therapeutics, Araclon Biotech S.L., AC Immune SA, Johnson & Johnson, and others—are advancing new therapies to enhance the MCI treatment landscape. Among the most promising pipeline candidates are LEQEMBI (lecanemab), KISUNLA (donanemab), and additional emerging therapies currently in development.

  • In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Leqembi, developed by Eisai R&D Management Co., Ltd., for the treatment of Alzheimer’s disease. The approval was based on the drug’s demonstrated ability to reduce amyloid beta plaques, a key marker of Alzheimer’s. It is indicated for patients in the early stages of the disease, including those with mild cognitive impairment or mild dementia.

  • Meanwhile, Eli Lilly’s Kisunla received approval from Japan’s Ministry of Health, Labor, and Welfare for adults with early symptomatic Alzheimer’s disease. Kisunla provides an option for early-stage patients, with the possibility of discontinuing treatment if amyloid levels drop below a defined threshold.

Key benefits of the Mild Cognitive Impairment market report:

  1. Mild Cognitive Impairment market report covers a descriptive overview and comprehensive insight of the Mild Cognitive Impairment Epidemiology and Mild Cognitive Impairment market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Mild Cognitive Impairment market report provides insights on the current and emerging therapies.

  3. Mild Cognitive Impairment market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Mild Cognitive Impairment market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Mild Cognitive Impairment market.

 

Got queries? Click here to know more about the Mild Cognitive Impairment Market Landscape

 

 

Mild Cognitive Impairment Overview

 

Mild Cognitive Impairment (MCI) represents a transitional phase between normal age-related cognitive changes and dementia, characterized by noticeable declines in memory, attention, and judgment that do not yet significantly interfere with daily functioning. Individuals with MCI face an elevated risk of progressing to Alzheimer’s disease or other dementias.

 

As prevalence continues to rise, especially in older populations, the importance of early detection and targeted management strategies is growing.

 

Mild Cognitive Impairment Market Outlook

 

Mild Cognitive Impairment (MCI) refers to a decline in cognitive abilities that exceeds typical aging but does not significantly disrupt daily functioning. Since MCI can progress to dementia, particularly Alzheimer’s disease, early detection and intervention are critical. Management typically focuses on modifying risk factors such as diet, hypertension, and physical activity. While pharmacological options like cholinesterase inhibitors (ChEIs) and memantine are sometimes used, especially in Alzheimer’s-related cases, non-drug strategies—including cognitive training, physical exercise, and lifestyle changes—remain central to care.

 

Given the absence of standardized therapies, individualized treatment is important, especially for patients with coexisting conditions. Although ChEIs are frequently prescribed in Alzheimer’s disease, their benefit in MCI is uncertain, often resulting in deprescribing. Agents like donepezil, rivastigmine, and galantamine provide only modest and temporary improvements, while memantine is better suited for moderate to severe cases.

 

With growing interest in advanced therapies, the MCI market is gaining momentum and opening avenues for innovation. Pipeline drugs such as Valiltramiprosate, Mirodenafil, and Hydromethylthionine mesylate (HMTM) hold potential to reshape market dynamics, though their long-term success remains to be determined.

 

Explore how the mild cognitive impairment market is rising in the upcoming years

 

Mild Cognitive Impairment Marketed Drugs

  • LEQEMBI (lecanemab): Biogen Inc./Eisai Co., Ltd.

  • KISUNLA (Donanemab): Eli Lilly and Company

 

Mild Cognitive Impairment Marketed Drugs

 

  • Valiltramiprosate (ALZ-801): Alzheon Inc.

  • Mirodenafil (AR1001): AriBio Co., Ltd.

  • Hydromethylthionine Mesylate (HMTM)/TRx0237: TauRx Therapeutics

 

Scope of the Mild Cognitive Impairment Market Report

 

  • Study Period: 2020-2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Mild Cognitive Impairment Companies: Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio, Inc., Anavex Life Sciences Corp., TauRx Therapeutics, Araclon Biotech S.L., AC Immune SA, Johnson & Johnson, and others

  • Key Mild Cognitive Impairment Therapies: LEQEMBI (lecanemab), KISUNLA (Donanemab), and others

  • Mild Cognitive Impairment Therapeutic Assessment: Mild Cognitive Impairment current marketed and Mild Cognitive Impairment emerging therapies

  • Mild Cognitive Impairment Market Dynamics: Mild Cognitive Impairment market drivers and Mild Cognitive Impairment market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Mild Cognitive Impairment Unmet Needs, KOL’s views, Analyst’s views, Mild Cognitive Impairment Market Access and Reimbursement

 

Download sample pages @ https://www.delveinsight.com/sample-request/mild-cognitive-impairment-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

 

 

Table of Contents

 

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Mild Cognitive Impairment Patient Share (%) Overview at a Glance

5. Mild Cognitive Impairment Market Overview at a Glance

6. Mild Cognitive Impairment Disease Background and Overview

7. Mild Cognitive Impairment Epidemiology and Patient Population

8. Country-Specific Patient Population of Mild Cognitive Impairment

9. Mild Cognitive Impairment Current Treatment and Medical Practices

10. Unmet Needs

11. Mild Cognitive Impairment Emerging Therapies

12. Mild Cognitive Impairment Market Outlook

13. Country-Wise Mild Cognitive Impairment Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Mild Cognitive Impairment Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Click here to read more about Mild Cognitive Impairment Market Outlook 2034

 

Related Reports:

Mild Cognitive Impairment Pipeline Insights, DelveInsight

“Mild Cognitive Impairment Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Mild Cognitive Impairment market. A detailed picture of the Mild Cognitive Impairment pipeline landscape is provided, which includes the disease overview and Mild Cognitive Impairment treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mild Cognitive Impairment Market: Epidemiology, Therapies, Companies Working, DelveInsight | Alzheon Inc., AriBio Co., Ltd., Eli Lilly, Novo Nordisk, AgeneBio, Inc., Anavex Life Sciences Corp., TauRx

Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Spasticity Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Spasticity Treatment Landscape @ Spasticity Pipeline Outlook

Key Takeaways from the Spasticity Pipeline Report

  • On 20 August 2025, Celgene conducted a study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity.
  • On 03 August 2025, Ipsen announced a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
  • DelveInsight’s Spasticity pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Spasticity treatment.
  • The leading Spasticity Companies such as Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc. and others.
  • Promising Spasticity Pipeline Therapies such as IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Baclofen, CORETOX®, BOTOX® and others.

Stay informed about the cutting-edge advancements in Spasticity treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Spasticity Clinical Trials Assessment

Spasticity Emerging Drugs Profile

  • MTR-601: Motric Bio

MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein – myosin 2 – in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function. MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy. Currently, the drug is in Phase II stage of its development for the treatment of Spasticity.

  • IPN10200: Ipsen

IPN10200 is a long‑acting botulinum neurotoxin candidate developed by Ipsen for the treatment of upper limb spasticity. Engineered for extended duration of effect, it aims to provide sustained relief from muscle hyperactivity by inhibiting acetylcholine release at neuromuscular junctions. As a targeted neurotoxin therapy, IPN10200 is designed to reduce muscle tone more consistently over time, potentially reducing injection frequency and improving patient convenience. Its development reflects Ipsen’s strategic focus on neuroscience and its commitment to advancing innovative therapeutic options in spasticity management. Currently, the drug is in Phase I/II stage of its development for the treatment of Spasticity.

The Spasticity Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
  • Spasticity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

Learn more about Spasticity Drugs opportunities in our groundbreaking Spasticity research and development projects @ Spasticity Unmet Needs

Spasticity Companies

Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc. and others.

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral

Spasticity Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Stay informed about how we’re transforming the future of Musculoskeletal @ Spasticity Market Drivers and Barriers, and Future Perspectives

Scope of the Spasticity Pipeline Report

  • Coverage- Global
  • Spasticity Companies- Motric Bio, Ipsen, Saol Therapeutics Inc, Elpida Therapeutics SPC, Celgene, Tris Pharma, Inc. and others.
  • Spasticity Pipeline Therapies- IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Baclofen, CORETOX®, BOTOX® and others.
  • Spasticity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Spasticity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Spasticity Pipeline on our website @ Spasticity Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Spasticity: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Spasticity– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name: Company Name
  9. Mid Stage Products (Phase II)
  10. MTR-601: Motric Bio
  11. Early Stage Products (Phase I/II)
  12. IPN10200: Ipsen
  13. Preclinical and Discovery Stage Products
  14. Drug Name: Company Name
  15. Inactive Products
  16. Spasticity Key Companies
  17. Spasticity Key Products
  18. Spasticity- Unmet Needs
  19. Spasticity- Market Drivers and Barriers
  20. Spasticity- Future Perspectives and Conclusion
  21. Spasticity Analyst Views
  22. Spasticity Key Companies
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/spasticity-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spasticity Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies